{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:06:47Z","timestamp":1787836007533,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaad.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:52:37Z","timestamp":1741611157000},"page":"188-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["In-transit melanoma metastases: Evaluation and management for the dermatologist"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3615-6432","authenticated-orcid":false,"given":"Anagha Bangalore","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Jakub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.03.005_bib1","series-title":"Melanoma of the Skin: AJCC Cancer Staging Manual","first-page":"563","author":"Gershenwald","year":"2017"},{"issue":"2","key":"10.1016\/j.jaad.2025.03.005_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2025.03.005_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2022.06.010","article-title":"Primary cutaneous melanoma features predict development of in-transit metastases\/satellite lesions: Mayo Clinic experience, 2010 to 2014","volume":"88","author":"Bangalore Kumar","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.03.005_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063137","article-title":"Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis","volume":"8","author":"Weide","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2025.03.005_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/ijd.16141","article-title":"Association of tumor molecular factors with in-transit metastasis in primary cutaneous melanoma","volume":"61","author":"Jakub","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2025.03.005_bib7","author":"Kenneth"},{"key":"10.1016\/j.jaad.2025.03.005_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-014-0096-3","article-title":"HF ultrasound vs PET-CT and telethermography in the diagnosis of In-transit metastases from melanoma: a prospective study and review of the literature","volume":"33","author":"Solivetti","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jaad.2025.03.005_bib9","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1007\/s00330-021-07852-7","article-title":"Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [(18)F]FDG PET\/CT","volume":"31","author":"Liberini","year":"2021","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/jso.25176","article-title":"Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins","volume":"118","author":"Gonzalez","year":"2018","journal-title":"J Surg Oncol"},{"issue":"14","key":"10.1016\/j.jaad.2025.03.005_bib12","first-page":"1340","article-title":"In-transit melanoma: an individualized approach","volume":"25","author":"Grotz","year":"2011","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.005_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jamcollsurg.2016.03.025","article-title":"Status of the regional nodal basin remains highly prognostic in melanoma patients with in-transit disease","volume":"223","author":"Gonzalez","year":"2016","journal-title":"J Am Coll Surg"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jamcollsurg.2013.12.025","article-title":"Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma","volume":"218","author":"Beasley","year":"2014","journal-title":"J Am Coll Surg"},{"issue":"5","key":"10.1016\/j.jaad.2025.03.005_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.sla.0000094440.50547.1d","article-title":"Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?","volume":"238","author":"Yao","year":"2003","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.jaad.2025.03.005_bib16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ejso.2020.10.028","article-title":"The role of sentinel lymph node status performed in melanoma patients with local recurrence or in transit metastasis","volume":"47","author":"Mattavelli","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.005_bib17","first-page":"3197","article-title":"The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma","volume":"34","author":"Gipponi","year":"2014","journal-title":"Anticancer Res"},{"issue":"28","key":"10.1016\/j.jaad.2025.03.005_bib18","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2014.55.4634","article-title":"Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis","volume":"32","author":"Spratt","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1440-0960.2003.00009.x","article-title":"Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene","volume":"44","author":"von Nida","year":"2003","journal-title":"Australas J Dermatol"},{"issue":"7827","key":"10.1016\/j.jaad.2025.03.005_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0140-6736(73)92103-X","article-title":"Remission of melanoma with D.N.C.B. treatment","volume":"2","author":"Malek-Mansour","year":"1973","journal-title":"Lancet"},{"issue":"4-5","key":"10.1016\/j.jaad.2025.03.005_bib21","first-page":"293","article-title":"Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years)","volume":"4","author":"Illig","year":"1984","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.005_bib22","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene","volume":"41","author":"Cohen","year":"1978","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jaad.2025.03.005_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00432-006-0182-9","article-title":"Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group","volume":"133","author":"Terheyden","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2025.03.005_bib24","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jid.2016.06.611","article-title":"Molecular profiling of immune activation associated with regression of melanoma metastases induced by diphencyprone","volume":"136","author":"Gulati","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.03.005_bib25","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/jid.2014.196","article-title":"Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights","volume":"134","author":"Gulati","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jso.23506","article-title":"Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma","volume":"109","author":"Damian","year":"2014","journal-title":"J Surg Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2025.03.005_bib27","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1111\/jdv.14422","article-title":"Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study","volume":"31","author":"Read","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2025.03.005_bib28","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/DSS.0000000000001603","article-title":"Responses to topical diphenylcyclopropenone as an adjunct treatment for in-transit melanoma: a tertiary referral center experience","volume":"44","author":"Veverka","year":"2018","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jaad.2025.03.005_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.03.005_bib30","first-page":"1","article-title":"Novel dermatologic uses of the immune response modifier imiquimod 5% cream","volume":"7","author":"Berman","year":"2002","journal-title":"Skin Ther Lett"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.005_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0560.2009.01290.x","article-title":"Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis","volume":"37","author":"Turza","year":"2010","journal-title":"J Cutan Pathol"},{"issue":"8178","key":"10.1016\/j.jaad.2025.03.005_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(80)91555-X","article-title":"Effect of azelaic acid on human malignant melanoma","volume":"1","author":"Nazzaro-Porro","year":"1980","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib33","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-011-9717-2","article-title":"Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil","volume":"30","author":"Florin","year":"2012","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.jaad.2025.03.005_bib34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/02841860500340340","article-title":"Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex)","volume":"44","author":"Ragnarsson-Olding","year":"2005","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jso.2930380409","article-title":"A role for topical 5-fluorouracil therapy in melanoma","volume":"38","author":"Ryan","year":"1988","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2025.03.005_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/CJI.0000000000000098","article-title":"Treatment of in-transit melanoma with intralesional bacillus Calmette-Guerin (BCG) and topical imiquimod 5% cream: a report of 3 cases","volume":"38","author":"Kibbi","year":"2015","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.005_bib38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.jaad.2025.03.005_bib39","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.005_bib41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jso.23702","article-title":"Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review","volume":"110","author":"Byers","year":"2014","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.005_bib42","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1245\/s10434-014-4199-z","article-title":"Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease","volume":"22","author":"Hassan","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jaad.2025.03.005_bib43","unstructured":"Clinical Trial NCT03655756. Accessed October 1, 2024. www.clinicaltrials.gov"},{"issue":"25","key":"10.1016\/j.jaad.2025.03.005_bib44","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.005_bib45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/CMR.0000000000000729","article-title":"Treatment of in-transit melanoma metastases using intralesional PV-10","volume":"31","author":"Thompson","year":"2021","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.005_bib46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/1097-0142(19880315)61:6<1071::AID-CNCR2820610603>3.0.CO;2-T","article-title":"Intralesional interferon-alpha therapy in advanced malignant melanoma","volume":"61","author":"von Wussow","year":"1988","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.005_bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.jaad.2025.03.005_bib48","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.005_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000440","article-title":"Efficacy of immune checkpoint inhibitors for in-transit melanoma","volume":"8","author":"Nan Tie","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.jaad.2025.03.005_bib50","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.005_bib51","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and treatment of in-transit melanoma metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2025.03.005_bib52","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1245\/s10434-016-5150-2","article-title":"Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma","volume":"23","author":"Dossett","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.005_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006629","article-title":"Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy","volume":"11","author":"Bhave","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.005_bib54","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0360-3016(99)00066-8","article-title":"Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience","volume":"44","author":"Seegenschmiedt","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.jaad.2025.03.005_bib55","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2025.03.005_bib56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.03.041","article-title":"The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - a multicenter cohort study","volume":"169","author":"Holmberg","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.005_bib57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2025.03.005_bib58","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","article-title":"1037O MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL)","volume":"32","author":"Ribas","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2025.03.005_bib59","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1245\/s10434-014-3671-0","article-title":"Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma","volume":"21","author":"Jiang","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.005_bib60","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.3747\/co.27.6523","article-title":"Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline","volume":"27","author":"Wright","year":"2020","journal-title":"Curr Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225004219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225004219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:44:37Z","timestamp":1766112277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225004219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0190962225004219"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.005","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-transit melanoma metastases: Evaluation and management for the dermatologist","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}